Amyloid diseases are a diverse group of disorders, characterized by the deposition of protein fibrils called amyloid in vital organs and tissues. They are severely debilitating, progressive, and often fatal within 5 years of diagnosis.
There are no FDA-approved diagnostics for systemic amyloidosis. Patients currently must undergo a multitude of diagnostic tests to arrive at a diagnosis, and none of these tests can visualize the extent and localization of amyloid deposition across the entire body.
Out of approximately 30 amyloid disorders, only 1 has an FDA-approved treatment. Current therapeutics for AL and ATTR work by reducing the pre-cursor protein, resulting in the reduction of new amyloid, which may slow disease progression. However, none of these therapeutics directly address already deposited toxic amyloid in organs and tissues.
Attralus is developing novel pan-amyloid targeting agents that have the potential to illuminate the disease with our first-in-class diagnostic imaging agent as well as directly bind and remove toxic amyloid fibrils from organs and tissues when armed with our therapeutics. Our diagnostic and therapeutic programs provide the potential for a holistic approach for detecting, monitoring, targeting, and clearing systemic amyloid.
is to improve the diagnosis and treatment of systemic amyloid diseases to increase patient survival and quality of life. Our approach targets the underlying pathology in all systemic amyloidosis diseases allowing us the potential to develop treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
and headquartered in South San Francisco, Attralus is a clinical-stage biopharmaceutical company focused on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company’s novel, pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis.